Rewalk Robotics Ltd
F:2RW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rewalk Robotics Ltd
F:2RW
|
IL |
Rewalk Robotics Ltd
ReWalk Robotics makes wearable robotic systems that help people with lower-limb mobility problems stand, walk, and train. Its core products are exoskeletons and rehabilitation devices used by people with spinal cord injuries, stroke survivors, and other patients who need help regaining movement. The company also sells related support, training, and service around these devices. Its customers are mainly hospitals, rehabilitation centers, clinics, veterans’ programs, and individual patients who qualify for the equipment. ReWalk earns money by selling or leasing its devices and by providing ongoing service, support, and training. In practice, it sits in a specialized corner of medical technology where the product is not a one-time machine sale but a clinical tool that often needs fitting, education, and after-sales support. That makes the business different from a normal medical device maker. ReWalk is focused on a narrow problem: helping people with serious leg-mobility loss move again with robotic assistance. Its value comes from combining hardware, clinical know-how, and patient support, which gives it a role in the rehab and mobility-care chain rather than a broad consumer or hospital equipment business.
ReWalk Robotics makes wearable robotic systems that help people with lower-limb mobility problems stand, walk, and train. Its core products are exoskeletons and rehabilitation devices used by people with spinal cord injuries, stroke survivors, and other patients who need help regaining movement. The company also sells related support, training, and service around these devices.
Its customers are mainly hospitals, rehabilitation centers, clinics, veterans’ programs, and individual patients who qualify for the equipment. ReWalk earns money by selling or leasing its devices and by providing ongoing service, support, and training. In practice, it sits in a specialized corner of medical technology where the product is not a one-time machine sale but a clinical tool that often needs fitting, education, and after-sales support.
That makes the business different from a normal medical device maker. ReWalk is focused on a narrow problem: helping people with serious leg-mobility loss move again with robotic assistance. Its value comes from combining hardware, clinical know-how, and patient support, which gives it a role in the rehab and mobility-care chain rather than a broad consumer or hospital equipment business.
Strategic partnership: Lifeward closed shareholder approval for a strategic transaction with Oramed, which will provide capital and access to ORMP-0801, an oral insulin candidate the company views as a high-upside biotech asset.
Revenue miss: 2025 revenue was $22.0 million, down from $25.7 million in 2024; management cited a distributor timing issue for AlterG and a sales-channel transition as the main causes.
Commercial reset: Management restructured sales into three focused channels (direct-to-patient, capital equipment, and payer engagement) and highlighted recent Medicare Advantage coverage wins with Aetna, Humana and UnitedHealthcare (16 million covered lives).
Product expansion: Lifeward acquired IP and the engineering team from Skelable for a powered upper-extremity exoskeleton; management expects a relatively low-barrier regulatory path and a commercialization timeline of roughly 18–24 months.
Improving profitability trends: Operating loss narrowed to $19.7 million and net loss to $19.9 million in 2025; operating cash usage fell to $16.8 million, and the company secured a $3.0 million loan from Oramed with an expected $10.0 million convertible note upon close.
No guidance: Given the transformation and pending Oramed close, Lifeward will not provide 2026 guidance at this time.
Commercial momentum signals: ReWalk units sold increased 22% YoY despite flat ReWalk revenue ($8.5 million), and the U.S. ReWalk pipeline had 104 qualified leads at year-end.
